Skip to main content
Media Coverage

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment [Microdose]

By July 15, 2025No Comments

In the shadow of headlines about the mental health crisis and the limits of current psychiatric care, one small biotech is making quiet but meaningful progress. Enveric Biosciences (NASDAQ: ENVB) announced this week that its lead drug candidate, EB-003, demonstrated a rapid therapeutic effect in a well-validated preclinical model for post-traumatic stress disorder (PTSD)—a condition that affects nearly 13 million Americans each year.

Full Article >>